Incyte Corporation Highlights New Oncology Data and Expands Formulation Development

Incyte Corporation (Nasdaq: INCY) announced that data from several oncology programs will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, scheduled for October 23‑27 2026. The company will deliver four rapid oral presentations covering Phase‑1 results across its solid‑tumor portfolio.

Key Program Updates

  • INCB161734 – An investigational, potent, selective, orally bioavailable KRAS G12D inhibitor. The Phase‑1 data will be discussed as part of an ongoing Phase‑3 study evaluating the compound as a first‑line therapy for patients with advanced pancreatic ductal adenocarcinoma (PDAC).
  • INCA338901 – A bispecific antibody targeting TGFβR2×PD‑1. Phase‑1 results will be presented within the context of an active Phase‑3 program investigating this agent as a first‑line treatment for microsatellite stable (MSS) colorectal cancer.

Incyte’s President and Global Head of Research and Development, Pablo J. Cagnoni, M.D., stated that the ESMO presentations will “illustrate Incyte’s commitment to advancing innovation for patients with cancer.”

Expanded Development of Subcutaneous Formulations

On July 20 2026, Halozyme Therapeutics announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme’s proprietary ENHANZE® drug‑delivery technology. INCA033989 is a first‑in‑class mutant calreticulin (mutCALR)-targeted monoclonal antibody currently in development for patients with mutCALR‑expressing myeloproliferative neoplasms (MPNs). The collaboration aims to enhance the subcutaneous formulation already in development, potentially enabling more convenient delivery and dosing regimens that may improve the treatment experience for patients.

Company Profile

Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware. The firm specializes in the discovery, development, and commercialization of proprietary small‑molecule drugs, primarily for oncology indications. As of July 16 2026, the company’s share price was USD 117.25, with a 52‑week high of USD 119.60 and a 52‑week low of USD 67.20. Incyte’s market capitalization stood at approximately USD 23.42 billion, and its price‑earnings ratio was 16.44.

These developments underscore Incyte’s continued focus on expanding its oncology pipeline and enhancing patient access through innovative drug delivery platforms.